Adjuvant and neoadj immunotherapy are increasingly incorporated in clinical care for patients with early stage
#lungcancer
. How can we enrich for the population most likely to benefit? Can ctDNA help?
Read together with
@JackWestMD
Here’s the latest from
@HopkinsThoracic
, hot off the press in
@NatureMedicine
; our pursuit of mutations with differential weights within the overall TMB lead us to the discovery of “persistent mutations”.
Curious? Read the full article:
@hopkinskimmel
Looking for a
#liquidbiopsy
read for the weekend? The
@jitcancer
special series, covering CTCs, cfDNA biology, existing & emerging technologies, applications in early detection, MRD & IO response monitoring, is now complete!
Visit the journal's homepage or
New liquid biopsy kid on the block! Here’s GEMINI developed by the very talented
@HopkinsKimmel
Human Genetics
#grad
student Daniel Bruhm: a
#machine
learning model for single-molecule genome-wide mutation profile detection. Just out in
@NatureGenet
Meet
@ValsamoA
at
#ISLB23
!
📅 Date: 21 November 2023
⏰ Time: 9:15 AM - 10:00 AM
Dr. Anagnostou is an Associate Professor of Oncology, Director of the Thoracic Oncology Biorepository, co-leader of the Molecular Tumor Board and co-director of the Lung Cancer Precision Medicine
Our work is now published online at
@CR_AACR
and represents the largest study of RAS genomic architecture to date, leveraging
#NGS
data from >600,000 mutations and >66,000 tumors across 51
#cancer
types.
Full text here
.
Getting ready for a stellar program at
#ELCC23
in Copenhagen! Will be presenting on lessons learned via repeat tumor tissue and liquid biopsies as tumors evolve under pressure of targeted therapies and immunotherapy.
@myESMO
@IASLC
@HopkinsThoracic
#LCSM
Thrilled to take upon this role together with
@josephcmurray
. Lots of work to do especially in linking next-generation sequencing with outcomes. This ties into the precision oncology efforts within the
@Hopkins_MTB
and more!
@Hopkins_MTB
is now
@theNCI
funded! Over the next few years will intensify our efforts to generate automated precision oncology decision-support systems linking genotypes with therapies at
@hopkinskimmel
& in the community. Thanks to our great clinical-genomic-informatics team!
So fortunate to celebrate the holiday season with the
@MolecularOncLab
! Cannot think of a more dynamic, creative and more importantly good-hearted group of people🙏
So fortunate to have been mentored by
@DavidRimm
and
@velculescu
and what a better occasion to get them both in one place than the
#AACR24
@AACR
journals reception!
The story starts several years back, when we discovered that mutation/neoantigen loss via chromosomal deletions is linked with acquired resistance to immune checkpoint blockade.
@CD_AACR
@HopkinsThoracic
@hopkinskimmel
Here’s the latest from
@HopkinsThoracic
, hot off the press in
@NatureMedicine
; our pursuit of mutations with differential weights within the overall TMB lead us to the discovery of “persistent mutations”.
Curious? Read the full article:
@hopkinskimmel
Phenomenal scientific program in
#CICON22
, thanks
@CancerResearch
and
@AACR
for the invitation to present! Here's a recap of day 2 (from a cancer immunology-enthusiast non-expert angle😏) with some notable publications reviewed at the meeting.
Read the 🧵
#Cancer
#Immunology
Persistent mutations-clinical version:There is more to TMB than just a number. There is more to targeted NGS than mutations in driver genes, integration of sequence & structural alterations detect "hard to lose" mutations that drive IO response
#OpenAccess
#ChristmasEveEve
with homemade
#Greek
kataifi (while baking I fell asleep for 2 hrs while putting the kids to sleep-turning out to be the secret ingredient :) :) ).
#MerryChristmas
Looking for a
#liquidbiopsy
read for the weekend? The
@jitcancer
special series, covering CTCs, cfDNA biology, existing & emerging technologies, applications in early detection, MRD & IO response monitoring, is now complete!
Visit the journal's homepage or
Excited to see what happens when
@ValsamoA
teams up to investigate targetable alterations in
#glioma
. Particularly proud of the resource for brain bio-availability of targeted therapies.
Proud to introduce the
@jitcancer
Special Series in Liquid Biopsies; together with
@md_stewart
& a phenomenal editorial team we have been working for over a year to put together a state-of-the-art series to discuss LB biology, technology, clinical utility and applications.
#Thread
Study Shows Utility of ctDNA Dynamics as Early Therapy Response Endpoint. A study by researchers at Johns Hopkins and the Canadian Cancer Trials Group demonstrated that early molecular therapy response correlated well with radiographic findings.
Here’s our latest, just out in
@NatMachIntell
: meet bigMHC an ensemble
#neuralnetwork
that transfer learned neoantigen immunogenicity! Experimental validation remains the holy grail, but is this feasible &scalable? Rhetoric question 😊. Read
@KarchinRachel
Countdown to
#ISLB23
! Cannot wait to re-connect with hundreds of
#liquidbiopsy
enthusiasts in Madrid in couple days! Whether you are joining in person or through on-demand access
@isliquidbiopsy
has put together a terrific scientific program👏.
Learn more:
#proudmentor
of Justin Huang, who masterfully presented his findings on T cell repertoire reshaping and priming of new T cell responses with radiation and immune checkpoint blockade for patients with NSCLC low on PDL1 or TMB, a population that we urgently need new tx strategies.
Our colleague Yixin chose to pay tribute to the advances we've published in
#cancergenomics
and
#multiomics
with a paper
@ValsamoA
et al. We'd like to say thank you to all of our authors, advisory board members, reviewers, and readers for driving science and society forward!